NASDAQ: SNYR) 1,600+ Nationwide Store Rollout – PPCB, SNGX, BTAI, HIT + Other Disruptive Stocks Moving Now!" src="https://www.abnewswire.com/upload/2025/08/1755526724.jpg" alt="Synergy Corp. (NASDAQ: SNYR) 1,600+ Nationwide Store Rollout – PPCB, SNGX, BTAI, HIT + Other Disruptive Stocks Moving Now!" width="225" height="225">Synergy CHC Corp. (NASDAQ: SNYR) is supercharging its retail expansion with a nationwide rollout of FOCUSfactor® Focus + Energy through EG America, the 6th largest U.S. convenience chain. The deal instantly places the functional brain health beverage in 1,600+ high-traffic locations, including Cumberland Farms, Turkey Hill, Tom Thumb (Albertsons Companies Inc. – NYSE: ACI), Loaf ’N Jug, and Minit Mart.
“This rollout brings FOCUSfactor’s cognitive-supporting, energy-boosting formula to millions of new consumers across the country,” said Jack Ross, CEO of Synergy CHC Corp. “EG America’s scale and innovation make them the perfect partner to accelerate our growth in the functional beverage space.”
Why It Matters
- Massive Reach: EG America delivers access to millions of shoppers nationwide.
- Functional Beverage Surge: A top-growth category, blending health benefits with convenience.
- Brain Health Boom: Rising demand for focus, memory, and performance products.
With a 25-year brand legacy, FOCUSfactor® is already carried by Costco (NASDAQ: COST), Walmart (NYSE: WMT), Amazon (NASDAQ: AMZN), CVS (NYSE: CVS), Walgreens (NASDAQ: WBA), among others, in the U.S., Canada, and the U.K. The EG America partnership strengthens Synergy’s convenience retail push, while international licensing deals in the UAE and Turkey further extend its global footprint. Backed by a $12.4M working capital surplus and multiple retail wins in the pipeline, Synergy expects more expansion announcements before year-end.
Other Big News Stocks to Watch
Alongside Synergy, several disruptive companies are making headlines:
- Propanc Biopharma Inc. (NASDAQ: PPCB): Approved to list on the Nasdaq Capital Market, now trading under symbol PPCB.
- Soligenix, Inc. (NASDAQ: SNGX): Received FDA Orphan Drug Designation for dusquetide (SGX945) in treating Behçet’s Disease following Phase 2a data.
- BioXcel Therapeutics, Inc. (NASDAQ: BTAI): Reported positive FDA pre-sNDA meeting feedback on a neuroscience therapy developed using AI.
- Catheter Precision Inc. (NASDAQ: VTAK): Achieved UK approval for its suture retention device, LockeT, signaling new international growth.
- Health in Tech Inc (NASDAQ: HIT) (Seeking Alpha Issues $5.70 Target)
Together, these emerging names underscore the wave of innovation across biotech, healthcare, and functional consumer markets — and Synergy (NASDAQ: SNYR) is positioning itself at the intersection of brain health and functional beverages, two megatrends driving consumer and investor attention into 2026.
Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content."TSR" is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. "TSR" authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. "TSR" has not been compensated to produce content related to "Any Companies" appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website.
Media Contact
Company Name: The Street Reports
Contact Person: Editor
Email: Send Email
Country: United States
Website: http://www.thestreetreports.com
